

Supplementary Table 2. Baseline characteristics of SARS-CoV-2 (+) population matched for each class of antihypertensive medication

Characteristic	Control (n = 535)	RAS blocker (n = 535)	p value	Control (n = 652)	CCB (n = 652)	p value	Control (n = 254)	BB (n = 254)	p value	Control (n = 286)	Diuretics (n = 286)	p value
Age, yr	68.2 ± 13.9	68.3 ± 12.4	0.871	66.0 ± 13.3	66.3 ± 13.5	0.704	67.6 ± 13.5	67.2 ± 13.9	0.731	66.4 ± 12.6	66.5 ± 12.6	0.950
Male sex	235 (43.9)	239 (44.7)	0.806	281 (43.1)	267 (41.0)	0.432	108 (42.5)	120 (47.2)	0.284	104 (36.4)	103 (36.0)	0.931
Heart failure	52 (9.7)	51 (9.5)	0.917	46 (7.1)	46 (7.1)	1.00	43 (16.9)	38 (15.0)	0.545	13 (4.6)	21 (7.3)	0.157
Prior MI	22 (4.1)	24 (4.5)	0.763	25 (3.8)	21 (3.2)	0.548	12 (4.7)	17 (6.7)	0.339	8 (2.8)	9 (3.2)	0.806
Diabetes	201 (37.6)	210 (39.2)	0.572	261 (40.0)	239 (36.7)	0.210	109 (42.9)	106 (41.7)	0.788	125 (43.7)	126 (44.1)	0.933
COPD or asthma	56 (10.5)	53 (9.9)	0.762	62 (9.5)	50 (7.7)	0.236	34 (13.4)	31 (12.2)	0.690	25 (8.7)	30 (10.5)	0.478
RAS blocker	-	-	-	413 (63.3)	411 (63.0)	0.909	155 (61.0)	156 (61.4)	0.927	248 (86.7)	249 (87.1)	0.901
CCB	285 (53.3)	280 (52.3)	0.760	-	-	-	120 (47.2)	133 (52.4)	0.249	162 (50.5)	124 (49.4)	0.800
Beta-blocker	110 (20.6)	117 (21.9)	0.601	121 (18.6)	110 (16.9)	0.425	-	-	-	53 (18.5)	54 (18.9)	0.915
Diuretics	37 (6.9)	39 (7.3)	0.812	109 (16.7)	118 (18.1)	0.511	45 (17.7)	47 (18.5)	0.818	-	-	-

Values are presented as mean ± SD or number (%).

SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; RAS, renin-angiotensin system; CCB, calcium-channel blocker; BB, beta-blocker; MI, myocardial infarction; COPD, chronic obstructive pulmonary disease.